CLL Support Association
8,872 members14,184 posts

More drug studies and trials on the way!

More drug studies and trials on the way!

Good to see the search for improved CLL treatments continues:

1) A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

This is a study evaluating the efficacy, safety, and pharmacodynamics of GS-9973 in subjects with chronic lymphocytic leukemia (CLL), etc.

See also Dr Jeff Sharman's post about this trial at:

2) Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (includes CLL and SLL)

Purpose: To determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab


2 Replies

Thanks Neil, there does seem to be a lot going on. Dr Sharman's blog is really helping to translate the new work and approaches in an understandable way. The landscape is changing we are fortunate to have someone so able to convey thoughts and map this for us.

Your post reminds me of words spoken at recent group meetings by clinical researchers. It is going to become increasingly important to have a consultant with a special interest in CLL on your team able to navigate the growing number of clinical trials available at research hospitals.


I have never met Dr Sharman, but have the highest regard for him based on the amount of comitment he makes to building a bridge between the patient and the medical world he is a part of through his blogs. he goes into great detail on every aspect of CLL and to have someone who is highly placed in the treatment and design of treatments who reaches out and explain in a clear way to CLLers. I like his candid comments and also the fact he holds out hope to the frightened sufferer that good things are coming. His blog is a must read


You may also like...